TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05304455
Drug: subcutaneous Low Molecular Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study: NCT05145543
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 NaCl % (Saline) (5 ml) will be applied
Study: NCT05145543
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
Study: NCT06383650
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
Study: NCT00002439
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05926869
Drug: Clindamycin and Dapsone gel for 03 months
Normalized name: dapsone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
Study: NCT05262751
Drug: Ofev®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofev®
Study: NCT05631704
Drug: VH4524184
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4524184 will be administered.
Study: NCT05631704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT05941247
Drug: Hemay005 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9.
Study: NCT06016218
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
Study: NCT06379542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets/day for 7-14 days
Study: NCT05299255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo as control group.
Study: NCT06078228
Drug: Propofol - Fentanyl- Atracurium
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: investigate the reliability of preanesthetic ultrasound measurements of the carotid artery FTc and the internal jugular vein collapsibility index in predicting hypotension during the induction of general anesthesia.
Study: NCT05391360
Drug: Freethiadine placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
Study: NCT04996433
Drug: algorithm-based study medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant.
Study: NCT04964349
Drug: Corticosteroids Acting Locally
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of jessener solution
Study: NCT05675813
Drug: standard CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
Study: NCT06184035
Drug: [177Lu]Lu-SN201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05333874
Drug: Neoadjuvant chemotherapy administered before surgical extraction of a tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
Study: NCT05072522
Drug: SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLB1028 capsules, oral, once daily in continuous 28-day cycles
Study: NCT06330935
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients will be randomized this arm C
Study: NCT05465590
Drug: MB1707
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism.
Study: NCT05092074
Drug: Vosevi 400/100/100 Oral Tablet
Normalized name: Vosevi 400/100/100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks
Study: NCT06031636
Drug: Oncolytic Adenovirus H101
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Study: NCT06031636
Drug: Programmed death receptor-1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Study: NCT05938725
Drug: Standard lymphodepletion regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lymphodepletion regimen
Study: NCT05727189
Drug: TR-01-XRR (1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release form
Study: NCT05727189
Drug: TR-01-XRR (2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release form
Study: NCT06115902
Drug: TQB2102 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Study: NCT05727189
Drug: TR-01-XRR (3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release form
Study: NCT05727189
Drug: TR-01-XRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release form
Study: NCT05727189
Drug: TR-01-XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release form
Study: NCT05727189
Drug: TR-01-IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator
Study: NCT05727189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06492447
Drug: Against HER 2-ADC Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.
Study: NCT06437951
Drug: Fexuprazan Injection
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/40/80 mg
Study: NCT06437951
Drug: Fexuprazan tablet
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg
Study: NCT05613777
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinylestradiol (EE) and levonorgestrel (LNG)
Study: NCT04693039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Study: NCT00329212
Drug: San Huang Xie Jin Tang
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05337553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
Study: NCT05003492
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infected patients will receive the standard therapy for COVID-19 for 14 days
Study: NCT05461287
Drug: QLS31904
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS31904 ONLY
Study: NCT04853446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
Study: NCT05757557
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
Study: NCT05970705
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
Study: NCT04341155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
Study: NCT05922982
Drug: norepinephrine weaning protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol
Study: NCT05922982
Drug: norepinephrine weaning protocol and guided by the HPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
Study: NCT06274398
Drug: TAF/EVG rectal insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
Study: NCT06274398
Drug: Matching placebo rectal insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
Study: NCT01433393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00417014
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04983979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo given titrated according to potassium at a dose to 5 or 10g
Study: NCT00000611
Drug: progestins
Normalized name: PROGESTINS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000611
Drug: calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05271682
Drug: FHND6091
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHND6091 capsules
Study: NCT05969522
Drug: GlucoCorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
Study: NCT05942820
Drug: BWC0977
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Study: NCT05942820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977
Study: NCT05208047
Drug: CGT9486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.
Study: NCT06466278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2dd2
Study: NCT04785118
Drug: Hyoscine N Butylbromide
Normalized name: Hyoscine N butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
Study: NCT05474989
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose LSD
Study: NCT05189704
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
Study: NCT05676801
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
Study: NCT04736589
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
Study: NCT06321250
Drug: JMKX003948
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive JMKX003948 tablets until disease progression
Study: NCT06526377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05937867
Drug: HS-10353 Capsules 30 mg, Oral, QN for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10353 Capsules 30 mg
Study: NCT05937867
Drug: HS-10353 Capsules 50 mg, Oral, QN for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10353 Capsules 50 mg
Study: NCT05937867
Drug: HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05937867
Drug: HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06273813
Drug: Ketorolac Tromethamine 15 MG/ML
Normalized name: ketorolac tromethamine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
Study: NCT06435949
Drug: Fentanyl (as Citrate)
Normalized name: fentanyl (as citrate)
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
Study: NCT04724720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment plus placebo
Study: NCT05351320
Drug: WX-0593 Tablets
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
Study: NCT05351320
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy
Study: NCT04965675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to eptinezumab will be administered per schedule specified in the arm.
Study: NCT06285617
Drug: 1-week predisone+1-week celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
Study: NCT06285617
Drug: 6-weeks predisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
Study: NCT05821556
Drug: Simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study: NCT05821556
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study: NCT05222425
Drug: Xagrotin
Normalized name: Naprotin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: A herbal compound
Study: NCT04707664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
Study: NCT05378334
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
Study: NCT05378334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
Study: NCT05266651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets for one month duration
Study: NCT05216224
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study: NCT05764239
Drug: SYNB1934v1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
Study: NCT05764239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
Study: NCT06221072
Drug: JMT103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg by subcutaneous injection every 4 weeks
Study: NCT06221072
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg by intravenous drip (100mL:4mg) every 4 weeks
Study: NCT05467293
Drug: 0.3% YP-P10 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: YP-P10 Ophthalmic Solution
Study: NCT05467293
Drug: 1% YP-P10 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: YP-P10 Ophthalmic Solution
Study: NCT05467293
Drug: YP-P10 Placebo Ophthalmic Solution (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)